
MIRA Pharmaceuticals, Inc. (MIRA) Stock Ticker
Market factors today
Unlock the full MIRA picture
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
MIRA stock facts
| Ticker symbol | MIRA |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $37.8M |
| CEO | Erez Aminov |
| Employees | 2 |
| Headquarters | Miami, FL, US |
| IPO date | 2023-08-03 |
| Website | mirapharmaceuticals.com |
What you can see for MIRA on Tickr
Live MIRA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MIRA report.
Rankings
FAQ
What is the ticker symbol for MIRA Pharmaceuticals, Inc.?
The ticker symbol for MIRA Pharmaceuticals, Inc. is MIRA, listed on the NASDAQ Capital Market.
What is MIRA?
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from…